Meet Dr. Clay Siegall of Seattle Genetic

Back in the year 1998, Dr.Clay Siegall co- founded the Seattle Genetics. He serves as the company’s president and Chief Executive officer and also as the chairman of the company’s board. As a scientist by training, driven by his passion to help cancer patients, Dr. Clay Siegall co- founded Seattle Genetics. Portraying good leadership, Clay has although guided the company to its position in the development of antibody –drug conjugates abbreviated (ADCs). Under his leadership, the company secured the FDA approval of its first ADC product, ADCETRIS, back in the year 2011. The ADC product, ADCETRIS, has been approved in over 65 countries making it an international brand.

Dr. Clay earlier worked with Bristol-Myers Squibb Pharmaceutical Research Institute for six good years, the National Institutes of Health for 3 years and the National cancer institute prior to establishment of the Seattle Genetics. Clay Siegall also serves in other leadership positions including the board of directors of Washington Roundtable, Ultragenyx Pharmaceutical and the Alder Bio Pharmaceuticals. He has also received several awards such as the Math and Natural Sciences, Pacific Northwest Ernst & Young Entrepreneur of the year 2012 and the University of Mary land Alumnus of the year 2013, all good indicators of his success. Clay holds a B.S in Zoology and a Ph.D. in genetics from the university of Maryland and George Washington University respectively. He has written over seventy publications and also holds about 15 patients.

In an interview with the ideamensch, Dr. Siegall recommended people to study and learn as much as they can, interact with people in possession of deep knowledge and wide experience in diverse fields to become successful entrepreneurs. He also said their company’s collaboration with other industries and innovators taking part in oncology drug development is one strategy that has helped them in the growing of their business.

Dr. Clay Siegall said that the target he wants to achieve is to be able and treat cancer patients in a better way than what is being done today. He added that he has been working towards this for about thirty years and he is still doing it.